<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="therapeutic effects. Lopinavir and ritonavir (LPV/r) is considered a promising" exact="treatment" post="option for COVID-19 based on the 2003 SARS treatment"/>
 <result pre="promising treatment option for COVID-19 based on the 2003 SARS" exact="treatment" post="experience.23 However, care should be taken when administering because"/>
 <result pre="are consistently detected near positive criteria from day 4 of" exact="treatment" post="despite the continued use of antiviral agents. The authors"/>
 <result pre="virus level or improves symptoms or is &quot;recommended&quot; for COVID-19" exact="treatment" post="based on this case report alone. Regardless of the"/>
 <result pre="believe that LPV/r is a promising antiviral agent for the" exact="treatment" post="of COVID-19. However, it is clear that well-designed studies"/>
 <result pre="disease 2019 in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 pneumonia monitored by quantitative RT-PCRJ Korean Med"/>
 <result pre="RT-PCRJ Korean Med Sci2020356e7932056407 2ChuCMChengVCHungIFWongMMChanKHChanKSet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax200459325225614985565 3ChanKSLaiSTChuCMTsuiETamCYWongMMet al.Treatment"/>
 <result pre="coronavirus pneumonia imported into Korea from Wuhan, China: implication for" exact="infection" post="prevention and control measuresJ Korean Med Sci2020355e6132030925"/>
</results>
